ADORA2A and Parkinson disease: The selective A2AR antagonists was developed as novel nondopaminergic agents for PD [11] and provides antiparkinsonian benefit without causing or worsening dyskinesia, which is one of the most inconvenient side effects of dopaminergic therapy [12].